Dario Sangiolo

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi et al. · The Lancet Oncology · 2014 · 328 citations · Full text

Surgical Oncology, Medicine, Standard Treatment +6

Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors

Dario Sangiolo · Journal of Cancer · 2011 · 133 citations · Full text

Cell Therapy, Immunology, Immunotherapy +16

Involvement of Chemokine Receptor 4/Stromal Cell–Derived Factor 1 System during Osteosarcoma Tumor Progression

Eliana Perissinotto, Giuliana Cavalloni, Francesco Leone et al. · Clinical Cancer Research · 2005 · 131 citations · Full text

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers

Dario Sangiolo, Emanuela Martinuzzi, Maja Todorovic et al. · International Immunology · 2008 · 130 citations · Full text

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

Ymera Pignochino, Carmine Dell’Aglio, Marco Basiricò et al. · Clinical Cancer Research · 2013 · 107 citations